Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rigosertib - Onconova Therapeutics

Drug Profile

Rigosertib - Onconova Therapeutics

Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; ON-01910Na; Rigosertib sodium; SyB C-1101; SyB L-1101

Latest Information Update: 09 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onconova Therapeutics
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Onconova Therapeutics; SymBio Pharmaceuticals
  • Class Amino acids; Antineoplastics; Small molecules; Sulfones
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Solid tumours
  • Phase I Head and neck cancer
  • No development reported Chronic lymphocytic leukaemia; Ovarian cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Squamous cell cancer

Most Recent Events

  • 03 Sep 2019 Additional efficacy data from a phase II extension trial in Myelodysplastic syndromes released by Onconova Therapeutics
  • 22 Aug 2019 Onconova Therapeutics and M.D. Anderson Cancer Center complete a phase II trial in Myelofibrosis (PO) (NCT02730884)
  • 07 Aug 2019 Onconova Therapeutics announces intention to submit NDA to regulatory body of Europe for higher-risk myelodysplastic syndromes (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top